Dianthus Therapeutics, Inc.
76.78USD
-1.7500 (-2.23%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on DNTH.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 1 | 1 | 2 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -61 | -47 | -70 | -40 | -35 | -33 | -32 | -30 |
| Net Income | -50 | -41 | -64 | -37 | -32 | -30 | -28 | -25 |
| EPS (Diluted) | -$0.90 | -$0.85 | -$1.52 | -$0.97 | -$0.88 | -$0.82 | -$0.82 | -$0.74 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)